A total of 11 studies with available HRs and their 95% CIs for PFS have been included in the meta-analysis, with a total of 3505 CLL patients, 422 patients were mutant SF3B1 and other 3083 patients were wild-type SF3B1. Overall, the pooled HR evaluating SF3B1 mutation on PFS was 1.81(95%CI 1.33-2.46, P<0.001) by random effects model for the existence of a significant heterogeneity(I2=78.9%, P<0.001), which suggested that SF3B1 mutation was significantly associated with worse prognosis for CLL in PFS (Figure 2A). Here, SF3B1 is linked to B-cell chronic lymphocytic leukemia.